← FDA DRUG APPROVALS

FDA ANDA · ANDA202732

HEPARIN SODIUM

Sponsor: SHENZHEN TECHDOW

APPLICATION
ANDA202732
TYPE
ANDA
ORIGINAL APPROVAL
2014-06-12
LATEST ACTION
2022-02-15
ROUTE
INTRAVENOUS, SUBCUTANEOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

HEPARIN SODIUM PRESERVATIVE FREEPrescription
HEPARIN SODIUM 1,000 UNITS/ML · INJECTABLE · INJECTION

Approval history

2022-02-15Labeling · Supplement 13 · standardAP
2022-02-15Labeling · Supplement 14 · standardAP
2014-06-12UNKNOWN · OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →